Bortezomib (aka as velcade or PS-341) is used in the clinic to treat multiple myeloma (MM)
and mantle cell lymphoma (Dou and Zonder, 2014). In addition to the pharmacokinetic …

The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib
inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are …

Due to an unmet clinical need for treatment, the first in class proteasome inhibitor,
bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an …

8.1 Background Bortezomib (1, Velcade, formerly PS-341) is an intravenously administered
first-in-class proteasome inhibitor that was approved by the FDA in 2003 for the treatment of …

The relatively recent clinical success of bortezomib, particularly in multiple myeloma, has
established the validity of the proteasome as a viable target for anticancer drug …

Multiple myeloma remains incurable despite available therapies, and novel therapies that
target both tumor cell and bone marrow microenvironment are urgently needed. Preclinical …

With the approval by the US Food and Drug Administration of bortezomib for the treatment of
multiple myeloma and mantle cell lymphoma, the proteasome was clinically validated as a …

Background: Bortezomib is a reversible inhibitor of proteasome proteins in mammalian cells.
Bortezomib is proven to be cytotoxic to a number of tumor cells by disrupting their normal …

Bortezomib represents the first proteasome inhibitor to have shown antitumour activity in
both solid and haematological malignancies. Inhibition of the proteasome degradation …

The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple
myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition …